The Delhi High Court's Division Bench held that product-to-claim mapping is indispensable for patent infringement, even in anticipatory suits. In a dispute between Zydus Lifesciences and E.R. Squibb…
Gaurav Mishra · 26 Jun 2026
Daewoong Pharmaceutical challenged the Controller's rejection of its crystalline SGLT inhibitor patent before the Delhi High Court. The core question: does improved dissolution and stability satisfy the Section…
Gaurav Mishra · 24 Jun 2026
In Frimline v. K-SMATCO, Delhi HC granted interim relief over patent IN 382949, citing strong prima facie infringement of Frimline’s pharmaceutical formulation.
Sowmya S Murthy · 10 Nov 2025